Sells generic and biosimilar medicines, over-the-counter products, and treatments for neurological, respiratory and other conditions to pharmacies, wholesalers and health care providers worldwide.
10-K for FY2025, filed Feb 3, 2026We are a biopharmaceutical company, enabled by a world-class generics business. For over 120 years, our commitment to bettering health has…View ↗
We are one of the leading generic pharmaceutical companies in the United States. We market more than 350 generic prescription products in…View ↗
Our innovative medicines portfolio in the United States includes our core therapeutic area of central nervous system (“CNS”), with a strong…View ↗
Our product and service portfolio includes generic medicines, biosimilar medicines, innovative medicines, OTC products, a distribution…View ↗
Our innovative medicines business is focused on delivering innovative solutions to patients and providers via medicines, devices and…View ↗
Most revenue comes from customers buying medicines and other goods, generally on credit after shipment; licensing arrangements also generate payments for intellectual-property rights and sales-based milestones or royalties.
8-K, filed Sep 3, 2026 10-K for FY2025, filed Feb 3, 2026Teva does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects…View ↗
Revenue from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product. This…View ↗
Licensing arrangements performance obligations generally include intellectual property (“IP”) rights, certain R&D and contract…View ↗
Revenue from sales-based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of…View ↗
$17.3B
10-K for FY2025, filed Feb 3, 2026
$17.3B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Sale of Goods
Sold outright
10-K for FY2025, filed Feb 3, 2026 |
85%
FY2022: 86%
|
Sale of Goods, FY2025
$14.6B Sources
|
Sold outright |
|
Licensing Arrangements
Licensed
|
3.9%
FY2022: 1.4%
|
Licensing Arrangements, FY2025
$678M Sources
|
Licensed |
|
Distribution
Sold outright
|
9.0%
FY2022: 10%
|
Distribution, FY2025
$1.6B Sources
|
Sold outright |
|
Other
Sold outright
|
2.5%
FY2022: 2.9%
|
Other, FY2025
$423M Sources
|
Sold outright |
U.S. generic medicines are sold mainly to retail drug chains, mail-order distributors and wholesalers; through Anda, Teva distributes products to pharmacies, pharmacy chains, hospitals and physician offices.
10-K for FY2025, filed Feb 3, 2026
Yes. It kept 8 cents of every revenue dollar as net income in FY2025 and turned 7 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 3, 2026
Open tableView ↗
8-K, filed Apr 29, 2026
In addition, on April 29, 2026, the Company issued a press release announcing that it has entered into a definitive agreement to acquire…View ↗
Growing. Revenue grew 9% in 4 years, from $15.9B in FY2021 to $17.3B in FY2025, about 2% a year.
Japan venture sold
The older report described a business venture in Japan with Takeda; the latest says Teva sold the venture, which included generic and legacy products.
10-K for FY2022, filed Feb 10, 2023 10-K for FY2025, filed Feb 3, 2026In Japan, one of our key markets within our International Markets segment, we operate a majority of our business through a business venture…View ↗
On March 31, 2025, we divested our Teva-Takeda business venture in Japan, which included generic products and legacy products. Since the…View ↗
Plans to divest API business
The older report described sales of active pharmaceutical ingredients to third parties; the latest says Teva intends to divest that business and focus on its core strengths.
10-K for FY2022, filed Feb 10, 2023 10-K for FY2025, filed Feb 3, 2026In addition to these three segments, we have other activities, primarily the sale of active pharmaceutical ingredients (“API”) to third…View ↗
Our product and service portfolio includes generic medicines, biosimilar medicines, innovative medicines, OTC products, a distribution…View ↗
Loading...